Long-term outcome with gold thiosulphate and tiopronin in 200 rheumatoid patients.
Two hundred rheumatoid patients were prospectively studied over a five-year period. One hundred and three received tiopronin (T) and 97 were treated with gold thiosulphate (GTS). At the end of the five-year period, similar percentages of patients dropped out because of lack of efficacy or because of major toxicities. Likewise, the percentages of patients still receiving the original drug in the two drug regimens at the 5th year of follow-up were 27.8% (GTS) vs. 25.2% (T), respectively.
Ferraccioli
G F
GF
Rheumatic Disease Unit (RDU), University Hospital of Parma, Italy.
Salaffi
F
F
Nervetti
A
A
Manganelli
P
P
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D006046:Gold / Q000627:therapeutic use*; D012971:Gold Sodium Thiosulfate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D012720:Severity of Illness Index; D013810:Therapeutic Equivalency; D008625:Tiopronin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D006046:Gold; D008625:Tiopronin; D012971:Gold Sodium Thiosulfate